2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007020155v1 18/5/1399    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chapman, A. B. Search for Related Content PubMed PubMed Citation Articles by Chapman, A. B.

Autosomal Dominant Polycystic Kidney Disease: Time for a Change?

Emory University School of Medicine, Atlanta, Georgia

Address correspondence to: Dr. Arlene B. Chapman, Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322. Phone: 404-712-1993; Fax: 404-727-5563; E-mail: arlene.chapman{at}emoryhealthcare.org

Diagnosis and treatment of autosomal dominant polycystic kidney disease (ADPKD) is rapidly changing. Cellular pathways that involve the polycystins are being mapped and involve the primary cilium, intracellular calcium and cAMP regulation, and the mammalian target of rapamycin (mTOR) pathway. With the use of new imaging approaches, earlier diagnosis of hepatic cystic disease is possible, and measurement of kidney and cystic growth as well as kidney blood flow is possible over relatively short periods. PKD gene type, gender, proteinuria, and the presence of hypertension relate to the rate of kidney growth in ADPKD. On the basis of risk factors for progression to ESRD and the pathogenic roles that intracellular cAMP and mTOR play in cystogenesis, novel therapies are now being tested, including maximal inhibition of the renin-angiotensin system, inhibition of renal intracellular cAMP using vasopressin V2 receptor antagonists, and somatostatin analogues, as well as inhibitors of mTOR. This review addresses the current understanding of the pathogenesis and the natural history of ADPKD; accuracy and reliability of diagnostic approaches in utero, childhood, and adulthood; the value of reliable magnetic resonance imaging to measure disease progression early in the course of ADPKD; and novel therapeutic approaches that are being evaluated in ADPKD.

This article has been cited by other articles:

				B. Yang, N. D. Sonawane, D. Zhao, S. Somlo, and A. S. Verkman Small-Molecule CFTR Inhibitors Slow Cyst Growth in Polycystic Kidney Disease J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1300 - 1310. [Abstract] [Full Text] [PDF]

				R. W. Lehrich and A. Greenberg When Is It Appropriate to Use Vasopressin Receptor Antagonists? J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1054 - 1058. [Abstract] [Full Text] [PDF]

				O. Ibraghimov-Beskrovnaya Molecular pathogenesis of ADPKD and development of targeted therapeutic options Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3367 - 3370. [Full Text] [PDF]

				T. Weimbs Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1 Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1423 - F1432. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673